| 沸点 | 715.75° C |
| 熔点 | 211-213° C |
| 折光率 | 1.67 |
| 敏感性 | 对热、空气敏感 |
| 溶解性 | DMSO 3 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
| 存贮条件 | 储存温度 2-8℃,充氩保存 |
| 密度 | 1.3000 |
| 应用 | An inhibitor of multiple tyrosine kinases |
| 产品介绍 | Imatinib(STI571)是多靶点抑制剂，对 v-Abl，c-Kit和PDGFR的IC50分别为0.6 μM，0.1 μM和0.1 μM。 |
| 备注 | Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. |
| 生化机理 | Description:IC50 Value: 100 nM (PDGFR) [1]; 100 nM (c-Kit) [2]Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.in vitro: In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively [1]. Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR [2]. Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively |
| 别名 | 伊马替尼; 4-((4-甲基-1-哌嗪基)甲基)-N-(4-甲基-3-(4-(3-吡啶基)-2-嘧啶基)氨基)苯基)苯甲酰胺;;STI571;STI 571;STI-571; imatinib;4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)phenyl)benzamide |
伊马替尼
Imatinib (STI571) （订货以英文为准）
编号：I124963
CAS号：152459-95-5
分子式：C29H31N7O
分子量：493.60
| 产品名称 | Imatinib (STI571) |
| 中文名称 | 伊马替尼 |
| CAS号 | 152459-95-5 |
| 分子式（M.F.） | C29H31N7O |
| 分子量（M.W.） | 493.60 |
| 储存条件 | -20°C储存;充氩 |
搜索质检报告(COA)
搜索MSDS
相关产品
¥ 1890.00
CR-070S-1台
¥ 98.00
sh5670-1片
¥ 98.00
sh024578-1片
¥ 120.00
sh02432-250mL
¥ 120.00
sh024431-250mL
¥ 120.00
sh024430-250mL
党沛 
